Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis.
Intranasal corticosteroids (INSs) are the most efficacious medication for the treatment of allergic rhinitis. In 2006, the Joint Task Force of the American College of Allergy, Asthma, and Immunology, and the American Academy of Allergy, Asthma, and Immunology, published a white paper on the potential over-the-counter switch of INS (Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: Position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 96:514-525, 2006). The concern of the paper was the safety of the use of these agents without oversight by a health care professional. The objective of this paper was to review published literature on the safety of INS since the publication of the task force white paper. Recent studies, which evaluated topical and systemic adverse events associated with ciclesonide (CIC), fluticasone furoate (FF), mometasone furoate (MF), triamcinolone acetonide, fluticasone propionate, budesonide, and beclomethasone dipropionate were summarized. In general, no significant topical or systemic complications were observed in these studies, although none were >1 year in duration. The newer formulations of topical corticosteroids for allergic rhinitis, such as CIC, FF, and MF, which have less systemic bioavailability, may be safer for long-term use. New studies continue to add to the reassurance of the safety of INSs in the treatment of allergic rhinitis but still do not answer the question if these agents are appropriate for long-term use without oversight by a health care professional.
Department of Pediatrics and Medicine, University of Tennessee Health Science Center, Memphis, USA. michael.blaiss@gmail.com
Michael S
MS
Blaiss
D000281:Administration, Intranasal; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects*; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects; D000068298:Fluticasone; D006801:Humans; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage / Q000009:adverse effects; D011282:Pregnenediones / Q000008:administration & dosage / Q000009:adverse effects; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D000730:Androstadienes; D011244:Pregnadienediols; D011282:Pregnenediones; D000068656:Mometasone Furoate; D019819:Budesonide; D000068298:Fluticasone; D014222:Triamcinolone Acetonide; C523187:fluticasone furoate; D001507:Beclomethasone; C120481:ciclesonide